In hematological malignancies which express HLA class II molecules, immunotherapy may be directed to HLA class II restricted antigens. We investigated whether it is possible to engineer HLA class II restricted T cells with both antigenspecific cytolytic activity and the capacity to produce high amounts of cytokines. CD4
Introduction
Patients relapsing from leukemia after allogeneic stem cell transplantation can successfully be treated by donor lymphocyte infusions (DLI), due to the graft-versusleukemia (GVL) response of the donor-derived T cells. [1] [2] [3] [4] However, DLI is also associated with graft-versus-hostdisease (GVHD). Several studies have illustrated that depletion of CD8 + T cells from the DLI may preserve the beneficial GVL reactivity without the induction of GVHD, indicating that the CD4 + T lymphocytes may play an essential role in the antileukemic reactivity. [5] [6] [7] [8] [9] [10] The mechanism by which the CD4 + T cells contribute to the GVL response is, however, not known. CD4 + T cells have been suggested to elicit the antileukemic response via the induction of minor histocompatibility antigen (mHag)-specific CD8 + T cells. 5 In addition, mHag-specific CD4 + T-helper cells have been reported to mature dendritic cells and enhance the expansion of mHag-specific cytotoxic T lymphocytes in vitro. 11 Alternatively, we have demonstrated that CD4 + T cells are capable of exerting direct cytolytic activity against leukemic cells.
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Cellular immunotherapeutic approaches based on the adoptive transfer of T lymphocytes may require large cell numbers. Large numbers of T cells with a defined antigen specificity can be acquired by retroviral transfer of the T-cell receptor to peripheral-blood-derived T lymphocytes. Until now, the application of retroviral transfer of TCRs has mainly been limited to the transfer of HLA class I restricted TCRs. [15] [16] [17] [18] [19] [20] However, the specificity of HLA class II restricted T lymphocytes can also be transferred to other T cells. [21] [22] [23] Previously, we demonstrated the retroviral transfer of a dual-specific TCR recognizing both an antigenic peptide in the context of HLA class I and an antigenic peptide in the context of HLA class II. 21 Furthermore, an MHC class II restricted chicken OVA 323À339 peptide-specific TCR was functionally transferred to murine CD4 + T helper cells. 22, 23 Effective immune responses have been shown to depend on both CD4 + and CD8 + T lymphocytes. 24, 25 In the absence of CD4 helper cells, CTLs were less protective against challenge with a pathogen. Furthermore, helper T lymphocytes have been found to be important for the development of T-cell memory. 24, 26, 27 Without help supplied by CD4 + T cells, T-cell memory generation can be severely hampered, as reflected by both decreased proliferation and diminished capacity to exert effector functions. Immune responses against leukemic cells might therefore also be more efficient when both T-cell subsets functionally contribute.
For cellular immunotherapy, it may be beneficial if both helper and cytolytic effector functions could be combined in one T-cell subset. We investigated whether it is possible to generate T cells with both HLA class II restricted cytolytic activity and the capacity to produce significant amounts of cytokines. As a model, we redirected human peripheral-blood-derived T cells by retroviral transfer of an HLA class II restricted TCR specific for the mHag dead box RNA helicase Y (DBY). 28 We generated TCR-transferred CD4 + T-cell clones that exerted specific cytolytic activity against DBY expressing EBV-LCL, and expanded specifically upon antigenspecific stimulation. Furthermore, the TCR-transferred CD4 + T-cell clones produced high amounts of cytokines upon DBY-specific stimulation. Since it could be hypothesized that CD8 + T cells are superior to CD4 + T cells to exert cytolytic effector functions, we generated DBY-TCR-transduced CD8 + CTLs, and characterized the effect of additional transfer of the CD4 coreceptor to optimize the interactions between CTL and target cells. TCRtransduced CD8 + CTLs without CD4 had comparable cytolytic activities as the TCR-transduced CD4 + T cells. The cytolytic activities improved when the TCR-transduced CD8 + T cells were additionally transduced with CD4. However, the combination of cytolytic activity and the capacity to produce high amounts of cytokines was only found in the TCR-transduced CD4 + T cells, since the TCR-transduced CD8 + T cells produced only low amounts of cytokines even after cotransfer of CD4. These results demonstrate that redirected T cells can be generated with cytolytic capacity and the ability to produce high amounts of cytokines by transfer of CD4 + T cells with an HLA class II restricted TCR.
Results
Functional analysis of the DBY-TCR-transduced CD4 +
T-cell clones
The TCRab usage of the male-specific mHag-DBYrecognizing T-cell clone JBB4 was determined by RT-PCR (data not shown). The TCRa chain was encoded by an in-frame gene rearrangement of AV1S4 and J39, and the TCRb was based on the combination of BV5S6 and BJ2S7 according to the nomenclature described by Arden et al. 29 In the IMGT nomenclature, these TCR chains are named AV8S3 and BV5S4, respectively. AV1 in combination with eGFP and BV5 in combination with DNGF-R were cloned into retroviral vectors. PBMCs from HLA-DQ5-negative donors (to prevent the generation of potentially self-reactive T cells) were stimulated with Leuko-A, and transduced on day 2 with the TCRa and TCRb chains of JBB4 or mock control vectors. On day 5, the transduced T cells were sorted based on eGFP and DNGF-R expression (data not shown), and plated single cell per well by FACS. Sorted T cells were expanded by nonspecific stimulation, and the functionality of the TCR-transduced T-cell clones was examined using cytotoxicity, proliferation, and cytokine production assays. Figure 1 shows the results of the TCR-transduced CD4 + T-cell clones that were cytotoxic and/or produced high amounts of cytokines, which comprised approximately 40% of the T-cell clones obtained. The TCRtransduced CD4 + T cells exerted upto 26% of specific cytotoxicity against the male-patient-derived EBV-LCL in a 4 h 51 Cr-release assay. The percentages of antigenspecific cytolytic activity increased for all TCR-transduced CD4 + T-cell clones after 19 h (Figure 1a ). The cytolytic activity against the HLA-identical EBV-LCL derived from the female donor was lower than 6% after 19 h (data not shown). Most TCR-transduced T cells proliferated specifically after mHag-specific stimulation with the patient EBV-LCL (Figure 1b) . Analysis of the production of the cytokines IFNg and IL-4 demonstrated that CD4 + T-cell clones with a Th0, Th1, and Th2 phenotype had been obtained. More than 1000 pg/ml of IFNg was produced by 10 of the 28 TCR-transduced CD4 + T cells after stimulation with the male-patientderived EBV-LCL and 11 TCR-transduced CD4 + T-cell clones produced more than 500 pg/ml of IL-4 ( Figure  1c) . A variety of TCR-transduced CD4 + T-cell clones were obtained. Some T-cell clones combined cytokine production with cytolytic activity, whereas others were cytokine producers without cytolytic capacity, and others were antigen-specific killers without the production of IFNg or IL-4. After stimulation with the EBV-LCL derived from the female donor, the production of IFNg was for all T-cell clones lower than 40 pg/ml, and the production of IL-4 was lower than 60 pg/ml (data not shown).
Mock-transduced CD4
+ T cells did not show any cytolytic activity, proliferation, and cytokine production after stimulation with EBV-LCL of donor or patient (data not shown).
DBY-specific reactivity of TCR-transduced T cells
To demonstrate that the antigen recognized by the TCRtransduced T cells on the patient-derived EBV-LCL was the male mHag DBY, TCR-transduced CD4 + T cells were tested against DBY-peptide pulsed-donor-derived EBV-LCL. Specific lysis was observed against both the patientderived EBV-LCL and the DBY-peptide pulsed-donorderived EBV-LCL (Figure 2a) . No cytolytic activity was observed against the female-donor-derived EBV-LCL. To confirm that the TCR-transferred CD4 + T-cell clones could specifically recognize endogenously processed DBY, cytolytic activity was analyzed against the DBYtransduced female-donor EBV-LCL. DBY-transduced, but not nontransduced or mock-transduced, donor EBV-LCL were lysed by the TCR-transduced CD4 + T cells (Figure 2b ). For comparison, the parental T-cell clone from which the TCR was originally derived was also included. Stimulation of the TCR-transduced CD4 + T cells with the patient-derived EBV-LCL or DBYpeptide-loaded donor EBV-LCL induced the production of the cytokines IFNg and/or IL-4 ( Figure 2c ). In conclusion, the TCR-transduced T cells recognized endogenously processed DBY expressed by malepatient-derived EBV-LCL.
Comparison of TCR-transduced CD4 + and CD8 + T-cell clones
To analyze whether transfer of the HLA class II restricted DBY-TCR to CD8 + CTLs would lead to the generation of T cells with higher cytolytic activity, we compared the cytolytic activity of TCR-transduced CD4 + T cells and TCR-transduced CD8 + T cells in 4 and 19-h 51 Cr-release assays. We observed no significant difference in specific cytolytic activity between the two T-cell subsets ( Figure  3a) . No cytotoxicity (o4%) was observed against the donor-derived EBV-LCL (data not shown). Analysis of the antigen-specific proliferation indicated that the TCR-transduced CD4 + and TCR-transduced CD8 + T cells had comparable proliferative capacities (Figure 3b ). In Functional transfer of HLA class II restricted TCR LT van der Veken et al contrast, we observed differences in the amounts of cytokines produced after antigen-specific stimulation. The TCR-transduced CD8 + T-cell clones produced low amounts of cytokines. Whereas no more than 70 pg/ml of IFNg and 170 pg/ml of IL-4 was produced by the TCR-transduced CD8 + T-cell clones, the TCR-transduced CD4 + T-cell clones produced upto 800 pg/ml of IFNg and 1800 pg/ml of IL-4 after stimulation with the patient-derived EBV-LCL (Figure 3c ). Mock-transduced CD8 + T cells did not show any cytolytic activity, proliferation, and cytokine production after stimulation with EBV-LCL of donor or patient (data not shown). In summary, DBY-TCR-transferred CD8 + T cells showed cytolytic activity and proliferation similar to TCRtransduced CD4 + T cells, but produced significantly lower amounts of cytokines.
CD4 coreceptor transfer to TCR-transduced CD8 + T cells
To investigate whether additional expression of the CD4 coreceptor could further enhance the specific cytolytic activity and cytokine production of the TCR-transduced CD8 + T cells, we cotransferred the CD4 molecule to the TCR-transduced CD8 + T cells. The TCR-transduced CD8 + T-cell clones were retrovirally transduced with the CD4 coreceptor, and subsequently FACS sorted based on the expression of CD4. The expression levels of the introduced CD4 molecules on the TCR-transduced CD8 + T-cell clones were comparable with the expression levels of CD4 on unmodified CD4 + T cells (data not shown). Figure 4a and b shows the data from seven representative TCR-transduced CD8 + T-cell clones with and without the and IFNg by the TCR-transduced T-cell clones was determined after stimulation with the patient-derived EBV-LCL for 24 h. After stimulation with the donorderived EBV-LCL, the production of IL-4 was o60 pg/ml and the production of IFNg was o40 pg/ml (data not shown). The experiments were performed twice in triplicate.
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LT van der Veken et al introduction of CD4. Figure 4a shows the cytolytic activity of the TCR-transduced CD8 + T-cell clones. To determine differences in antigen-specific cytolytic activity, the lysis was measured at a 9 h time point at which the lytic activity had not reached a plateau level. After cotransfer of CD4 to the TCR-transduced CD8 + T-cell clones, five out of seven TCR-transduced CD8 + T-cell clones showed increased antigen-specific cytolytic activity against the patient-derived EBV-LCL. However, the cytokine production by the CD4-cotransferred TCRtransduced CD8 + T-cell clones was still very low in comparison with the production by the TCR-transduced CD4 + T-cell clones (Figure 4b ). Whereas the TCR-transduced CD4 + T-cell clones produced upto 800 pg/ml of IFNg and 1800 pg/ml of IL-4 after stimulation with the patient-derived EBV-LCL (Figure 3c ), the CD4-cotransferred TCR-transduced CD8 + T-cell clones produced only upto 150 pg/ml of IFNg and 440 pg/ml of IL-4. In + and CD8 + T-cell clones was compared after stimulation with the patient-derived EBV-LCL for 24 h. After stimulation with the donorderived EBV-LCL, the production of IL-4 was o50 pg/ml and the production of IFNg was o60 pg/ml (data not shown). All the experiments shown in this figure were performed twice and in triplicate. + T-cell clones was determined after 24-h stimulation with the patient-derived EBV-LCL and DBY-peptide pulsed-donor-derived EBV-LCL. After stimulation with the donor-derived EBV-LCL, the production of IL-4 was o70 pg/ml and the production of IFNg was o20 pg/ml (data not shown). The experiment was performed in duplicate.
Functional transfer of HLA class II restricted TCR LT van der Veken et al conclusion, cotransfer of CD4 did not generate TCRtransduced CD8 + T-cell clones producing amounts of cytokines as high as the TCR-transduced CD4 + T-cell clones, although improved cytolytic activity was observed for the majority of the TCR-transduced CD8 + T-cell clones.
Mechanism of target cell lysis of the TCR-transduced T-cell clones
Since the cytolytic activities of the TCR-transduced CD4 + T-cell clones and TCR-transduced CD8 + T-cell clones were found to be comparable, we investigated whether the 'helper' and 'cytotoxic' T cells applied similar mechanisms for their target cell lysis using perforin and granzyme-B blocking experiments. The TCR-transduced CD4 + T-cell clones and TCR-transduced CD8 + T-cell clones were preincubated with the Ca 2+ chelator EGTA, which captures extracellular Ca 2+ , and, subsequently, a 51 Cr-release assay was performed. In the 19-h 51 Cr-release assay, EGTA preincubation almost completely blocked the specific cytotoxicity of all TCRtransduced T-cell clones and the parental T-cell clone (Figure 5a ). When increasing amounts of the perforin inhibitor CMA were preincubated with the T cells, a dose-dependent inhibition of lysis was observed. At the highest CMA concentration (1000 nM) specific target cell lysis was completely blocked (Figure 5b ). High amounts of CMA were found not to be toxic to both target cells and T cells, since no increased spontaneous 51 Cr release by the target cells was observed, and no decrease in the number of viable T cells was indicated by eosine staining. In conclusion, these data demonstrate that the CD4 + T cells applied the same mechanism for target cell lysis as the CD8 + T cells.
Discussion
In this study, we demonstrated that redirected CD4 + T lymphocytes with cytolytic capacity and different helper phenotypes can be generated by the retroviral transfer of an HLA class II restricted TCR to peripheral-bloodderived T cells. The TCR used in this study was a TCR specific for the male-specific mHag DBY in the context of HLA-DQ5. TCR-transduced T cells were sorted based on the expression of the marker genes eGFP and DNGF-R. The TCR-transferred CD4 + T cells possessed cytolytic activity, proliferated, and produced high amounts of cytokines after antigen-specific stimulation with EBV-LCL-expressing DBY. The cytokine profiles of the TCRtransferred CD4 + T-cell clones indicated that all different T helper subsets were represented. TCR-transduced CD4 + T-cell clones were detected, which produced both IFNg and IL-4 (Th0), or IFNg (Th1), or IL-4 (Th2). The TCR-transferred CD4 + T cells exerted DBY-specific cytolytic activity upto 26% in a 4-h 51 Cr-release assay, Cr-release assays, the cytolytic activities of the TCR-transduced T-cell clones and the parental T-cell clone were analyzed after preincubation with increasing amounts of CMA, varying from 2.5-1000 nM. The data shown are the average of three independent experiments performed in triplicate at an E/T ratio of 10:1.
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LT van der Veken et al and the specific lysis increased upto 100% after 19 h. Although TCR-transferred CD4 + T-cell clones were obtained that were as cytolytic as the parental JBB4 T cell clone (Figures 2b and 5) , variation was observed in the levels of cytolytic activity of the TCR-transferred T-cell clones. We previously demonstrated that TCRtransferred T-cell clones can have different expression levels of the introduced TCR, explaining the observed variation in cytolytic activity. 19 Different TCR expression levels might arise due to differences in the expression levels of the retrovirally encoded TCRab chains or competition for cell surface expression with the endogenous TCR and mixed TCR dimers.
Based on the potent cytolytic effector function of CD8 + T cells, we hypothesized that T cells with higher antigenspecific cytolytic activity could be obtained by transferring the DBY-TCR to CD8 + CTL. However, CD8 + T cells transferred with the DBY-TCR had comparable cytolytic activity. The proliferative capacity was also similar to TCR-transduced CD4 + T cells, but the cytokine production was significantly lower. Since the TCR-transferred CD4 + T cells expressed the coreceptor relevant for the interaction with HLA class II molecules and the TCRtransferred CD8 + T cells did not, we investigated whether expression of CD4 could increase the specific cytolytic activity and cytokine production of the TCR-transferred CD8 + T cells. By additional retroviral transfer, the CD4 molecule was cotransferred to the TCR-transferred CD8 + T cells. The CD4 molecule enlarges the overall affinity of the TCR with its antigenic peptide-HLA complex through binding to the b2 domain of the HLA class II molecule. 30 It has been proposed that the dependency on CD4 is determined by the number of antigenic peptide-HLA complexes on the target cell surface. 31 The TCR requires a critical number of antigenic peptide-HLA complexes on the target cell surface for CD4-independent recognition. In correspondence with the function of CD4, we observed improved cytolytic activity by cotransferring CD4 to the TCR-transduced CD8 + T cells. The cytokine production was, however, still very low in comparison with the production by the TCR-transduced CD4 + T cells. Since the marker gene expression level and thus the expression level of the introduced DBY-TCR between the TCR-transduced CD4 + and CD8 + T cells were comparable, differences in the specific cytokine production of both subsets cannot be due to differences in TCR expression of the TCR-transduced CD4 + and CD8 + T cells. A potential disadvantage of TCR gene transfer to other ab T cells is the formation of mixed TCR dimers. Chains of the introduced TCR can pair with the endogenous TCR chains naturally expressed by the TCR-transferred T cells. Since the specificity of the mixed TCR dimers is unknown, autoreactivity cannot be excluded. 19, 32 The number of T cells with different TCR chains and thus the chance to generate autoreactive T cells can be limited by TCR gene transfer to T cells with defined antigen specificity. We previously demonstrated the reprogramming of cytomegalovirus (CMV)-specific T cells into leukemia-reactive T cells by transferring a TCR specific for the mHag HA-2. 19 The amounts and type of cytokines produced by different T-cell subsets may have major impact on the eventual outcome of immune responses. T cells producing Th1 cytokines (IFNg and IL-2) have been shown to be responsible for antitumor reactivity. [33] [34] [35] Previously, we showed that HA-2-specific T cells isolated by tetramer during a strong GVL response produced large amounts of IFNg and no or low amounts of IL-4. 18 Furthermore, we recently demonstrated that T cells contributing to the GVL reactivity of DLI can be isolated based on their production of IFNg. 36 Thus, Th1 cytokines play a very important role in antitumor reactivity. Th2 and Tc2 cells have also been suggested to play a central role in the regulation of GVHD, graft rejection, and GVL responses. [37] [38] [39] We hypothesize that, in addition, significant amounts of cytokines have to be produced for effective antitumor reactivity. The previously isolated functional mHag-specific T cells that may have contributed to the on going GVL response, all produced more than 800 pg/ml of IFNg. 18 Since the large amounts of cytokines produced by DBY-TCR-transduced CD4 + T cells were not equaled by the TCR-transduced CD8 + T cells, TCR-transduced CD4 + T cells may be preferred for cellular immunotherapy. Furthermore, selection of effector cells with the desired cytokine profile might be possible, since TCR transfer to the CD4 + T cells generated T cells with all different Th phenotypes (Th0, Th1, and Th2).
The antitumor reactivity of DLI has been suggested to be mediated by CD8 + T cells of donor origin. 40 41 which was confirmed by our perforin-and granzyme-B-blocking experiments, CD4 + T cells may directly and effectively mediate cell lysis of HLA class II-expressing cell populations.
As a model, we used a TCR recognizing the mHag DBY in the context of HLA-DQ5. HLA class II restricted TCRs directed against hematopoiesis-specific antigens which are differentially expressed between the patient and donor can be very suitable for the treatment of hematological malignancies, 42 since HLA class II expression is not only found on hematopoietic progenitor cells, 43 B cells, 44 activated T cells, 44 and monocytes, 44 but also on many malignant hematopoietic cells. HLA class II expression has been demonstrated on acute myeloid leukemia, 45, 46 chronic myeloid leukemia, 47 acute lymphoblastic leukemia, 46, 48, 49 chronic lymphocytic leukemia, 46 ,49 multiple myeloma, 50 and hairy cell leukemia. 48 Thus, HLA class II restricted TCR-transferred CD4 + T cells combining cytolytic activity with cytokine production may therefore be very potent effector cells for the application of cellular immunotherapy.
In summary, we demonstrated that HLA class II restricted T cells can be obtained with both cytolytic and helper functions by the retroviral transfer of a TCR to peripheral-blood-derived T cells. TCR-transferred CD4 + T cells were generated that were cytolytic, had proliferative capacity, and produced high amounts of cytokines. Transfer of the DBY-TCR to CD8 + T cell produced T cells with comparable cytolytic activity as the TCR-
+ T cells, but, despite cotransfer of the CD4 coreceptor to the TCR-transduced CD8 + T cells, CD4 + T cells were superior to the CD8 + T cells in the production of the cytokines IFNg and IL-4. Hence, application of TCR-transferred CD4 + T cells might be a novel strategy, combining T-cell help with cytolytic activity, leading to improved efficacy of immunotherapy for HLA class II expressing hematological malignancies.
Materials and methods

T-cell clones
Previously, the CD4 + T-cell clone JBB4 was isolated from a male patient who developed acute GVHD after stem cell transplantation from his HLA genotypically identical sister.
12 JBB4 was demonstrated to recognize the malespecific mHag DBY in the context of HLA-DQ5. 28 The T-cell clone produced both IFNg and IL-4 after antigenspecific stimulation and exerted specific cytolytic activity against targets expressing DBY in the context of HLA-DQ5. 12 T-cell clones were cultured in Iscove's modified Dulbecco's medium (IMDM) (BioWhittaker, Verviers, Belgium) containing 10% pooled human serum and 100 IU/ml IL-2 (Chiron, Amsterdam, The Netherlands). Every 2 weeks, the T cells were stimulated with a mixture of 50 Gy irradiated allogeneic PBMCs, 50 Gy irradiated Epstein-Barr virus (EBV)-transformed B cells (EBV-LCL), 1 mg/ml leucoagglutinin (Leuko-A, Sigma, St Louis, USA), and 100 IU/ml IL-2.
Construction of the retroviral vectors and production of the retroviral supernatant
The TCRab usage of the JBB4 T-cell clone was determined by RT-PCR using primers covering the entire repertoire of known TCR chains. Table 1 shows the forward primers used for determination of the TCR AV gene used by the JBB4 T-cell clone. The common reverse primer used for the AV PCR was: 5 0 AGCAGATTAAACCCGGCCA3 0 . Table 2 shows the TCR BV primers used in combination with common BV reverse primer: 5 0 TTCTCTTGACCATGGCCATC3 0 . For all primers, the same PCR program was used. After the initial denaturation (5 min, 941C), 33 cycles were performed for denaturation (1 min, 941C), annealing (1 min, 601C), and elongation (1 min, 721C), followed by an extra elongation period of 7 min (721C). Subsequently, the identity of the PCR products was confirmed by sequencing. The TCRa and TCRb chains were cloned into bicistronic retroviral vectors containing the marker genes eGFP 51 and truncated nerve growth factor receptor (DNGF-R), 52 respectively. The Moloney murine leukemia virus-based retroviral vector LZRS and packaging cells j-NX-A were used. 53 j-NX-A packaging cells were /2S2  TRAV12-2/TRAV12-3  TCAGTGTTCCAGAGGGAGCCATTG  4  2S3  TRAV12-1  TCAATGTTCCAGAGGGAGCCACTG  5  3S1  TRAV17  GGAGTGTCTTTGGTGATTCTATGG  6  4S1  TRAV26-2  GCATTACTGTACTCCTATCTTTGGG  7  4S2  TRAV26-1  AGTAACTGTGTTTCTGACCTTTGGA  8  5S1  TRAV6  GTGTTTTGCTGATTTTGTGGCTTCA  9  6S1/ADV6S1  TRAV14/DV4  TTGTCACAGCTTCACTGTGGCTAG  10  7S1/7S2  TRAV1-1/TRAV1-2  TATGTTTCCATGAAGATGGGAGGC  11  8S1  TRAV13-1  GACAGCGCTGTTATCAAGTGTACT  12  8S2  TRAV13-2  TGACAACTCTATTATCAACTGTGCT  13  9S1  TRAV16  CGAGAAGCTCCTCTCTGTCTTTAAA  14  10S1  TRAV27  AGCCCTCAGTTTCTAAGCATCCAA  15  11S1  TRAV2  GGCTAGGGCTTCTCCTCAACTCTC  16  12S1  TRAV19  CAGACTGAAATTTCTGTGGTGGAG  17  13S1  TRAV22  GAGGGAGCCAATTCCACGCTGCG  18  14S1/ADV14S1/14S2  TRAV38-2/DV8/TRAV38-1  CCAGAGATGTCTGTGCAGGAGGCA  19  15S1  TRAV5  CGAGAGGGAGACAGCTCCGTTATA  20  16S1  TRAV3  GGAAGATCAGGTCAACGTTGCTGA  21  17S1/ADV17S1  TRAV23/DV6  CCAGAAAGGAGGGATTTCAATTATA  22  18S1  TRAV24  GGAGGGAGACAGCACCAATTTCAC  23  19S1  TRAV41  CTCGGTAGGAATAAGTGCCTTACA  24  20S1  TRAV4  CAAGAAGTGAACATAACCTGTAGCC  25  21S1/ADV21S1  TRAV29/DV5  AGCAAGTTAAGCAAAATTCACCATC  26  22S1  TRAV9-2  ATTCAGTGACCCAGATGGAAGGGC  27  23S1  TRAV21  CCAGAAGGAGAAAACTTGGTTCTC  28  24S1  TRAV10  ATCATCCTGGAGGGAAAGAACTGC  29  25S1  TRAV35  TCTTCAAGCATATTTAACACCTGGC  30  26S1  TRAV34  CCAAGAGGGAAAGAATCTCACCATA  31  27S1  TRAV39  CAGGAGGGAAAAAACTATACCATCT  32  28S1/DV28S1  TRAV36/DV7  TGACTAACTTTCGAAGCCTAC  33  29S1  TRAV30  TCCGAGAAGGGGAAGATGCTGTCA  34  30S1  TRAV20  TTGGCTGGTTGAGTGGAGAAGACC  35  31S1  TRAV40  CTAATTCTGATCTTAATGTTTGGAGG  36 32S1 TRAV25 CCTCAACTACTTTAAGCAATATACAG Functional transfer of HLA class II restricted TCR LT van der Veken et al transfected with the TCRa or TCRb chain containing retroviral vectors using a calcium phosphate transfection method (Life Technologies, Gaithersburg, USA), and after 2 days 2 mg/ml puromycin (CLONTECH Laboratories, Inc.) was added. The transfected j-NX-A cells were cultured on puromycin-containing medium for approximately 14 days, and, subsequently, 2 Â 10 7 cells were plated per T175 tissue culture flask (Greiner-Bio One, Frickenhausen, Germany) in 30 ml IMDM supplemented with 10% FBS without puromycin. The next day medium was replaced, and the following day retroviral supernatant was harvested, centrifuged, and frozen in aliquots at À701C. Likewise, a retroviral supernatant was produced encoding the CD4a molecule with marker gene DNGF-R. For the transduction of the donor-derived EBV-LCL with DBY, retroviruses were made encoding the DBY protein with the marker eGFP, or a fusion protein of the invariant chain (Ii) and the DBY epitope (HIENFSDIDMGE) (Ii-DBY epitope) with the marker gene DNGF-R. Fusion of the DBY epitope to the invariant chain enhances presentation of the epitope in the context of MHC. 54 As control vectors, retroviral vectors were used containing only eGFP or DNGF-R. Functionality of the retroviral constructs encoding the TCRa and TCRb chains was confirmed by transduction of the TCRa and TCRb chain-deficient Jurkat clone 76 and subsequent analysis of TCRab cell surface expression as reported previously. 18 Production of DBY-transduced EBV-LCL Donor-derived EBV-LCL were transduced with retroviral supernatants containing the DBY gene, or the Ii-DBY epitope or the DNGF-R control vector. The transduction was performed using recombinant human fibronectin fragments CH-296 55 (Bio Whittaker, Verviers, Belgium) as described. 51 The transduction efficiency as measured by the expression of the markers eGFP and NGF-R was analyzed by flow cytometry 3-5 days after transduction. Subsequently, the EBV-LCL were sorted on the basis of the expression of the marker genes eGFP or DNGF-R using a FACS Vantage (Becton Dickinson (BD), San Jose, USA). The donor-derived EBV-LCL, the patient-derived EBV-LCL, and the transduced EBV-LCL were used as target cells in the cytotoxicity assays and stimulator cells in the proliferation and cytokine assays. For the detection of the DNGF-R, a phycoerythrin (PE)-conjugated antihuman NGF-R mAb (Pharmingen, San Diego, USA) was used.
Generation of DBY-TCR-transduced T cells
Human peripheral blood T cells derived from HLA-DQ5-negative donors were stimulated with 1 mg/ml Leuko-A in IMDM supplemented with 10% pooled human serum and 100 IU/ml IL-2. At 2 days after stimulation, the T cells were transduced with a mixture of the JBB4 TCRaand TCRb-chain-encoding retroviral supernatants, or 1  1S1  TRBV9  GAGAGCAAAAGGAAACATTCTTGAAC  2  2S1  TRBV20-1  TCTGTGAAGATCGAGTGCCG  3  2S2  TRBV20-2  TCTGTGAACATCGAGTGCCG  4  3S1  TRBV28  TCTGGAATGTGTCCAGGATATG  5  4S1  TRBV29-1  GCTCTGAGGCCACATATGAGAG  6  5S1  TRBV5-1  CTTCAGTGAGACACAGAGAAAC  7  5S2/5S3/5S6  TRBV5-6/TRBV5-5/TRBV5-4  TGTGTCCTGGTACCAACAGG  8  5S4  TRBV5-8  TGTGTACTGGTACCAACAGG  9 6S3/6S6/6S8 TRBV27  GTGACTGATAAGGGAGATGTTCCT  22  15S1  TRBV24-1  GATCTCTGATGGATACAGTGTCT  23  16S1  TRBV14  AATCTTTATTGGTATCGACGTGTT  24  17S1  TRBV19  AGCTGAAGGGTACAGCGTCTCTC  25  18S1  TRBV18  CAGCTCCCAGAGGAAGGTCT  26  19S1  TRBV23-1  GTCACACAGACTCCAGGATATT  27  20S1  TRBV30  GGAACATCAAACCCCAACCTA  28  21S2/21S3  TRBV11-3/TRBV11-2  TCCCAGATATAAGATTATAGAG  29  21S1  TRBV11-1  CCCCAGATATAAGATTACAGAG  30  22S1  TRBV2  ATCTCAGAGAAGTCTGAAATATTCG  31  23S1  TRBV13  ATGCAGAGCGATAAAGGAAG  32  24S1  TRBV15  AAAGATTTTAACAATGAAGCAGAC  33  25S1  TRBV16 Functional transfer of HLA class II restricted TCR LT van der Veken et al control retroviral supernatants containing the marker genes eGFP or DNGF-R only. TCR-transduced eGFP + and DNGF-R + T cells were sorted single cell per well using a FACS Vantage. Flow-cytometric analysis illustrated that both CD4 + and CD8 + DBY-TCR-transduced T-cell clones were obtained. The mAbs used for flow cytometry were anti-human TCRab conjugated with PE-Cy5 (Immunotech, Marseille, France), anti-CD3, anti-CD4, and anti-CD8 mAbs conjugated with PE (BD). Part of the TCRtransduced CD8 + T-cell clones were subsequently transduced with the retrovirus encoding the CD4a molecule. The CD4-transduced T-cell clones were sorted based on the expression of CD4.
Cytotoxicity assay
Target cells were labeled with 100 mCi Na 2 51 CrO4 for 1 h at 371C, washed three times, and added to the effector cells at various effector/target ratios in a final volume of 150 ml of IMDM supplemented with 10% FBS in 96-well U-bottomed microtiter plates. In some experiments, target cells were loaded with DBY peptide (10 mg/ml) for 1 h at 371C and washed once. Blocking of Ca 2+ -dependent cytotoxicity was performed by preincubation of the effector cells with 5 mM EGTA (Sigma-Aldrich, St Louis, USA) for 30 min at 371C. To block perforinmediated cytotoxicity, effector cells were preincubated with 2.5-1000 nM concanamycin A (CMA) (SigmaAldrich, St Louis, USA) for 30 min at 371C. After washing, the effector cells were added to the target cells. Targets incubated in medium or 1% Triton X-100 were used for determination of the spontaneous and maximum release, respectively. The tests were performed in duplicate or triplicate. After 4, 9, or 19 h of incubation at 371C and 5% CO 2 , 25 ml of the supernatant was harvested and measured in a luminescence counter (Topcount-NXT, Packard). The percentage of specific lysis was defined as [(experimental releaseÀspontaneous release)/ (maximum releaseÀspontaneous release)] Â 100.
Proliferation assay and cytokine production
To measure the proliferative capacity and cytokine production of the T-cell clones, 2 Â 10 4 irradiated (50 Gy) stimulator cells per well of an U-bottomed 96-well plate were added to equal numbers of effector cells in a final volume of 150 ml of IMDM supplemented with 10% FBS, and incubated at 371C and 5% CO 2 . After 24 h, 80 ml supernatant was harvested to determine IFNg and IL-4 production by standard ELISA (Sanquin, Amsterdam, The Netherlands). After 72 h, 1 mCi
